Glucose Fresenius Kabi

Glucose Fresenius Kabi is a sterile aqueous solution for injection that contains glucose monohydrate as the active ingredient. It is supplied as a parenteral nutrition formulation without a specified strength, intended for intravenous administration. Manufactured in the European Union, the product is classified as a carbohydrate solution used to provide an energy source for patients who cannot receive nutrition orally or enterally and for correction of low blood glucose levels.

Glucose Fresenius Kabi is indicated for several clinical situations where intravenous carbohydrate delivery is required.

- Treatment of hypoglycemia when oral glucose is not feasible. - Component of parenteral nutrition regimens for patients unable to eat or absorb nutrients enterally. - Fluid and electrolyte replacement in conjunction with other intravenous solutions. - Support during perioperative periods to maintain blood glucose levels. - Management of metabolic disorders requiring controlled glucose infusion. - Use in pediatric or neonatal intensive care units where precise glucose administration is essential for growth and development.

The safety profile of Glucose Fresenius Kabi reflects the expected physiological responses to intravenous glucose administration.

Common: - Transient hyperglycemia that resolves with monitoring. - Mild local irritation at the infusion site. - Nausea or vomiting if administered rapidly. - Fluid overload in patients with compromised cardiac function. - Mild headache or dizziness during infusion. - Temporary increase in serum osmolality. - Mild taste alteration reported by some patients receiving peripheral infusion.

Serious: - Severe hyperglycemia leading to osmotic diuresis. - Hypersensitivity reactions such as rash, itching, or anaphylaxis. - Electrolyte imbalances, particularly hyponatremia or hyperkalemia. - Development of metabolic acidosis in patients with impaired renal function. - Risk of thrombophlebitis if infused through peripheral veins without proper dilution. - Severe hyperglycemia leading to osmotic diuresis.

When using Glucose Fresenius Kabi, clinicians should observe several precautions to ensure patient safety and optimal therapeutic effect.

- Assess baseline blood glucose and adjust infusion rate accordingly. - Monitor serum electrolytes, especially sodium and potassium, during prolonged administration. - Use caution in patients with renal or hepatic impairment due to altered glucose metabolism. - Avoid rapid infusion in individuals at risk for fluid overload or cardiac failure. - Ensure aseptic technique to prevent catheter-related infections. - Consider pediatric dosing guidelines separately from adult protocols. - Verify compatibility with other intravenous solutions before co‑administration.

Glucose Fresenius Kabi may interact with other medications or clinical conditions; awareness of these interactions helps prevent adverse outcomes.

Avoid: - Concomitant use with insulin or other hypoglycemic agents without dose adjustment, as it may cause severe hypoglycemia. - Co‑administration with high‑dose potassium chloride solutions, which can exacerbate hyperkalemia.

Use with caution: - Concurrent intravenous dextrose-containing fluids; monitor total carbohydrate load to avoid hyperglycemia. - Patients receiving beta‑blockers, as glucose metabolism may be altered. - Individuals with severe renal impairment; adjust infusion rate and monitor electrolytes closely. - Use with caution in patients on diuretics that affect fluid balance. - Patients on corticosteroids may experience increased glucose levels; monitor closely.